First orders for dental and nerve products
Orthocell has now received first purchase orders for our flagship collagen medical device products Striate+™ and Remplir, via our valued distribution partners.
September 26, 2022
Beyond the Medicine Cabinet Podcast | September 2022
Orthocell’s CEO and Managing Director Paul Anderson has featured on Beyond The Medicine Cabinet podcast to talk about regenerative nerve repair, and how Orthocell’s Remplir™ collagen nerve wrap is revolutionising surgery for patients with peripheral nerve injuries.
September 12, 2022
Appointment of exclusive distributor of Remplir™ in Australia
Orthocell has appointed Device Technologies as the exclusive distributor of Remplir™ for peripheral nerve repair in Australia.
September 7, 2022
VIDEO | Proactive Investors – September 2022
Orthocell’s Paul Anderson spoke with Andrew Scott at Proactive Investors to discuss to discuss the announcement that the Company had secured Device Technologies as the exclusive distribution partner for Remplir™ in the Australian marketplace.
September 7, 2022
Orthocell appoints Device Technologies as distributor of its nerve repair device in Aus, NZ
Orthocell’s distribution deal with Device Technologies has been featured in The West Australian, in this news article by business reporter Cheyanne Enciso.
September 7, 2022
Dr Boreham’s Crucible | July 2022
Orthocell was featured in the widely read column, Dr Boreham’s Crucible, written by respected small cap analyst and business journalist, Tim Boreham.
July 22, 2022
VIDEO | Proactive Investors – July 2022
Orthocell’s Paul Anderson spoke with Alisha Newell at Proactive Investors to discuss the Company’s strong position following the recently executed global exclusive licence and distribution agreement with BioHorizons Implant Systems Inc for $OCC’s Striate+™ dental membrane.
July 22, 2022
VIDEO | ShareCafe ‘Hidden Gems’ Webinar – July 2022
Orthocell CEO and Managing Director, Paul Anderson, recently participated in the ShareCafe Small Cap ‘Hidden Gems’ Webinar.
July 7, 2022
Striate+™ global exclusive license and manufacturing agreement with BioHorizons
Orthocell (ASX:OCC) has signed a global exclusive license and manufacturing agreement for its FDA-cleared dental product, Striate+™, with BioHorizons Implant Systems Inc – one of the largest dental implant companies in the world.
June 27, 2022
Remplir™ Channel 7 News feature
Clinical trial participant Damian Hall was featured in a national news story by Channel 7 News Reporter, Alison Fan, to discuss his path to continued mobility following a nerve repair procedure with Remplir™.
May 11, 2022